Ozempic users cut food spending by 5 percent within months

When people start taking appetite-suppressing drugs like Ozempic and Wegovy, their grocery bills shrink along with their waistlines. New research from Cornell University found that households reduce food spending by an average of 5.3% within six months of starting a GLP-1 medication — and the effect is even sharper for higher-income households, which cut spending by more than 8%.

The study, published in the Journal of Marketing Research, pairs survey data about medication use with actual transaction records from tens of thousands of American households. It's one of the most detailed real-world looks yet at how these drugs reshape everyday food choices.

The Shift in What People Buy

The spending cuts aren't random. Ultra-processed snacks took the biggest hit — spending on savory snacks dropped about 10%, with similar declines in sweets, baked goods, and cookies. Even basic staples like bread, meat, and eggs saw reductions. The only categories that gained ground were yogurt, fresh fruit, nutrition bars, and meat snacks.

Meals eaten outside the home fell even more steeply. Spending at fast-food chains, coffee shops, and limited-service restaurants dropped roughly 8%. For someone accustomed to a daily coffee-shop habit or quick lunch runs, that's a meaningful shift in routine and budget.

The pattern makes sense biologically. GLP-1 drugs, originally developed for diabetes, work by reducing hunger signals in the brain. With less appetite driving purchases, people naturally gravitate toward foods that feel satisfying in smaller portions — and skip the impulse buys that used to fill their carts.

What This Means Beyond the Checkout

For food manufacturers and restaurant chains, widespread GLP-1 adoption could reshape entire business models. If millions of Americans are eating less and choosing differently, companies will need to rethink package sizes, product formulations, and marketing strategies. Snack food makers face real pressure. So do fast-food chains built on volume and impulse sales.

For policymakers, the findings raise a quieter question: here's something that's shifting eating behavior at scale — not through taxes or warning labels, but through a biological mechanism that makes people simply want less. Whether that's good policy depends on your view of medication as a tool for public health, and whether you think appetite suppression is a sustainable approach to food spending and diet quality.

The research doesn't tell us whether these spending patterns stick long-term, or whether they reflect a genuine shift toward healthier eating or simply eating less overall. But it does show that the ripple effects of these drugs extend far beyond individual weight loss — they're reshaping what Americans buy, where they eat, and how much they spend.